文章：

乳腺癌中新型HER-2靶向疗法

Novel HER-2 Targeted Therapies in Breast Cancer

原文发布日期：23 December 2023

DOI: 10.3390/cancers16010087

类型: Article

开放获取: 是

英文摘要：

Human epidermal growth factor 2 (HER-2)-positive breast cancer represents 15–20% of all breast cancer subtypes and has an aggressive biological behavior with worse prognosis. The development of HER-2-targeted therapies has changed the disease’s course, having a direct impact on survival rates and quality of life. Drug development of HER-2-targeting therapies is a prolific field, with numerous new therapeutic strategies showing survival benefits and gaining regulatory approval in recent years. Furthermore, the acknowledgement of the survival impact of HER-2-directed therapies on HER-2-low breast cancer has contributed even more to advances in the field. The present review aims to summarize the newly approved therapeutic strategies for HER-2-positive breast cancer and review the new and exploratory HER-2-targeted therapies currently under development.

摘要翻译： 

人表皮生长因子受体2（HER-2）阳性乳腺癌约占所有乳腺癌亚型的15%-20%，具有侵袭性生物学行为且预后较差。HER-2靶向疗法的开发改变了该疾病的病程，对患者生存率和生活质量产生了直接影响。近年来，HER-2靶向治疗药物研发成果丰硕，多种新治疗策略显示出生存获益并获得监管批准。此外，针对HER-2低表达乳腺癌的靶向治疗对生存影响的确认，进一步推动了该领域的发展。本综述旨在总结新近获批的HER-2阳性乳腺癌治疗策略，并对目前正在开发的新型探索性HER-2靶向疗法进行评述。

原文链接：

Novel HER-2 Targeted Therapies in Breast Cancer